GlassScriptPhysician profile
Todd Allyn Baxter
NPI 1649200544
$529.78
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $122 · 2022: $35.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $146.41 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $102.84 | 2019-2020 | |
| Glaxosmithkline, LLC. | $86.68 | 2019-2022 | |
| Neos Therapeutics, LP | $49.76 | 2019 | |
| Kaleo, INC. | $30.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.25 | 2019 | |
| Sobi, INC | $19.04 | 2019 | |
| Medline Industries LP | $16.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.79 | 2022 | |
| Adlon Therapeutics L.P. | $13.30 | 2020 | |
| Genentech USA, INC. | $11.24 | 2020 | |
| Cranial Technologies, INC | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.